MedTrace Logo

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

NCT01064388 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-06-06

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and blood levels of AZD9742 after daily dosing for 14 days.

Conditions

  • Healthy

Interventions

DRUG

AZD9742

IV infusion, 15 days

DRUG

Placebo

IV infusion, 15 days

Sponsors & Collaborators

Principal Investigators

  • Andrew Shaw · AstraZeneca

  • Brendan Smyth · AstraZeneca

  • David Melnick · AstraZeneca

  • Ralph Schutz · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
23 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01064388 on ClinicalTrials.gov